Atibuclimab

CAS No. 2417175-94-9

Atibuclimab( —— )

Catalog No. M36910 CAS No. 2417175-94-9

Atibuclimab is a chimeric monoclonal antibody targeting CD14, consisting of a mouse variable region and a human IgG4 Fc region.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 196 Get Quote
5MG 350 Get Quote
10MG 534 Get Quote
25MG 818 Get Quote
50MG 1095 Get Quote
100MG 1431 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Atibuclimab
  • Note
    Research use only, not for human use.
  • Brief Description
    Atibuclimab is a chimeric monoclonal antibody targeting CD14, consisting of a mouse variable region and a human IgG4 Fc region.
  • Description
    Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    TNF
  • Recptor
    TNF
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2417175-94-9
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Henderson RD, Agosti JM, McCombe PA, et al. Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis. Medicine (Baltimore). 2021;100(42):e27421. ?
molnova catalog
related products
  • MOSLOFLAVONE

    MOSLOFLAVONE showed promising anti-inflammatory activity via inhibition of TNF-α and IL-1β with IC50 values of 0.71 μM and ?7.8 μM respectively.

  • Teneliximab

    Teneliximab (BMS 224819) is a chimeric monoclonal antibody and a tumor necrosis factor receptor superfamily member 5 (CD40) inhibitor that blocks CD40-CD40L interactions.

  • (Rac)-Benpyrine

    (Rac)-Benpyrine is a potent and orally active inhibitor of TNF-α.